Inactive Instrument

Parnell Pharmaceuticals Holdings Ltd Stock Nasdaq

AU0000XINEU9

Latest news: Parnell Pharmaceuticals Holdings Ltd

03-03	Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03-03	Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
12-17	Parnell Pharmaceuticals Holdings Ltd has entered into an agreement to acquire Noble Pharma, LLC.	CI
25-01-30	RCBC BidCo Pty Ltd proposed to acquire Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F).	CI
22-06-20	Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	CI
21-01-27	DW Healthcare Partners V, L.P. managed by DW Healthcare Partners completed the acquisition of a 29% stake in Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $2.5 million	CI
20-12-20	DW Healthcare Partners V, L.P. managed by DW Healthcare Partners made an offer to acquire Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $7.2 million.	CI
20-09-23	Parnell Pharmaceuticals Announces Nomovid Antiviral Nasal Spray	CI
19-10-13	Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Half Year Ended June 30, 2019	CI
19-04-04	Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Full Year Ended 31 December 2018; Provides Earnings Guidance for the Year 2019	CI
18-11-02	Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2018; Revises Revenue Guidance for the Year 2018	CI
18-08-03	Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018; Revised Earnings Guidance for the Full Year 2018	CI
18-04-28	Parnell Pharmaceuticals Holdings Ltd Reports Audited Earnings Results for the First Quarter Ended March 31, 2018; Revises Earnings Guidance for the Year 2018	CI

More news

Press Releases: Parnell Pharmaceuticals Holdings Ltd

25-01-21	Parnell Pharmaceuticals : Introduces New Veterinary Certificate in Anesthesia and Sedation	PU
24-05-15	Parnell Pharmaceuticals : Introduces Two New Sedation Products to Pet Care Product Line	PU
24-03-07	Parnell Pharmaceuticals : Welcomes Dr. Chelsie Estey as Vice President of U.S. Pet Care	PU
23-05-30	Parnell Pharmaceuticals : Adds Three Experts to Leadership Team	PU
23-05-30	Parnell Pharmaceuticals : Two New Territory Business Managers Help Parnell Better Serve Producers and Veterinarians	PU

More press releases

Managers and Directors: Parnell Pharmaceuticals Holdings Ltd

Manager	Title	Age	Since
Brad McCarthy CEO	Chief Executive Officer	50	2018-01-08
Joe Rosentel CTO	Chief Tech/Sci/R&D Officer	-	2021-08-31
Pablo Lamberto COO	Chief Operating Officer	-	2022-06-30

Director	Title	Age	Since
Brad McCarthy BRD	Director/Board Member	50	-
Alan Richard Bell CHM	Chairman	69	2005-12-31
Eric Moore BRD	Director/Board Member	-	2020-12-20

More insiders

Parnell Pharmaceuticals Holdings Ltd is an Australia-based company, which is engaged in offering the global veterinary pharmaceutical business marketing products in 14 countries. The Company operates sterile manufacturing facilities and offers digital technology platforms that integrate with the Companyâ€™s products to offer veterinarians and animal owners superior solutions for their animal health needs. The Company also provides a fully integrated animal health platform. The Companyâ€™s mySYNCH is a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. The Companyâ€™s products include GONAbreed, estroPLAN, and RESPIRmycin. GONAbreed is used for the treatment of cystic ovaries and used in cattle synchronization protocols. The estroPLAN is used in animals with unobserved or non-detected estrus in cattle undergoing synchronization protocols. The RESPIRmycin is used for the treatment of respiratory disease in beef and non-lactating dairy cattle.

Employees

Sector

More about the company